We can’t show the full text here under this license. Use the link below to read it at the source.
Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System
Neurological side effects linked to GLP-1 receptor agonist drugs reported to the FDA
AI simplified
Abstract
Among 28,953 neurological adverse event reports associated with glucagon-like peptide-1 receptor agonists, 19 distinct signals were identified.
- Common include dizziness, tremor, and taste disorder.
- The median time from treatment initiation to onset of neurological adverse events was 32 days.
- Nearly 45.28% of these adverse events occurred within the first 30 days of treatment.
- Different statistical methods confirmed the reliability of the identified signals.
- Findings indicate the necessity for increased clinical awareness regarding these potential adverse events.
AI simplified
Key numbers
28,953
NAE Reports
Total neurological adverse event reports linked to GLP-1 RAs in FAERS.
31 days
Median Time-to-Onset
Median time from GLP-1 RA initiation to NAE occurrence.
11.58%
Percentage of in Reports
Proportion of among all reported adverse events for GLP-1 RAs.